SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors digest a massive 27 billion dollar AI infrastructure deal with Meta, paired with analyst price target hikes and ongoing support from Nvidia. While some market participants are expressing concerns over share dilution and debt financing, the broader community remains heavily focused on the company's rapid scaling and its positioning as a key player in the AI compute sector.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is currently trending as investors weigh recent progress on a Nuclear Regulatory Commission materials license for its subsidiary against anticipation for the upcoming earnings report. The community remains divided, with some bulls highlighting the potential for nuclear energy to meet AI-driven power demand, while others express concerns over the company's pre-revenue status and recent insider share activity.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is experiencing significant retail momentum fueled by strong interest in its AI-driven real estate platform and optimism surrounding housing affordability legislation. Shareholders are actively debating the potential for a short squeeze, balancing excitement over the company's long-term transformation against concerns about broader market volatility and geopolitical pressures.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is surging toward all-time highs as investors position themselves ahead of a highly anticipated earnings report, fueled by reports of an HBM4 supply deal for Nvidia's new Vera Rubin systems. The community is actively debating whether the stock's massive rally is sustainable or if it represents a 'priced-in' event, with many bulls pointing to structural memory shortages and institutional accumulation as drivers for further growth toward the $500$600 range.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently trading in a tight consolidation range as investors monitor the company's progress on its Neutron rocket and backlog conversion, while anticipation builds for a broader industry re-rating tied to the upcoming SpaceX IPO. The community remains focused on the firm's expanding defense contracts and frequent launch cadence, often comparing it to a space-based "Uber" that serves as a key player in satellite deployment and national security.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is facing significant volatility ahead of its earnings release, with investors debating whether the stock's recent pullback is a buying opportunity or a reaction to shifting market sentiment toward optical connectivity. Community discussion is sharply divided between those pointing to robust revenue growth and essential data center infrastructure demand, and others concerned about aggressive institutional selling and perceived technical weakness.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors digest long-term clinical data, potential buyout speculation, and strategic marketing shifts following a period of suppressed share price action. The community is actively debating the company's valuation as a standalone commercial growth story versus its viability as a takeover candidate, while maintaining a strong focus on the competitive performance of Briumvi in the MS market.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following a significant $3 million insider purchase by Paul Manning, which has revitalized investor confidence despite recent volatility and capital raising efforts. The community remains hyper-focused on the company's upcoming Phase 3 prostate cancer trial results and the strategic potential for a multi-billion dollar buyout as the firm moves toward a planned BLA submission.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital is currently trending as investors speculate on a high-profile tenant announcement following the appointment of a new CFO with significant data center financing experience. While the community remains divided between those anticipating a major parabolic move based on upcoming project updates and those expressing frustration over delays in firm tenant news, active traders are closely monitoring volume spikes and momentum rotations.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is currently a focal point for investors due to extreme volatility driven by a high short interest, with many in the community speculating on a potential short squeeze. Sentiment is split between those viewing the company's AI-driven mortgage automation as a transformative industry disruptor and others wary of the stock's significant price decline and ongoing insider selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the...

Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade

The consensus price target hints at an 118.1% upside potential for Prothena (PRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Prothena (NASDAQ:PRTA) Shares Up 8.7% - Still a Buy?

Prothena (NASDAQ:PRTA) Trading 8.7% Higher - Should You Buy...

Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Analysts

Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) has earned a consensus rating of "Hold" from the eleven brokerages that are currently covering the firm, MarketBeat reports. Two equities...

Prothena To Buy Back Up To $100 Mln Of Shares

(RTTNews) - Prothena Corporation plc (PRTA) announced that its board has authorized a share repurchase plan allowing the company to buy back up to $100 million of its outstanding ordinary shares...

Prothena Announces up to $100 Million Share Repurchase Plan

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...

FY2026 EPS Estimates for Prothena Boosted by HC Wainwright

Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Investment analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Prothena in a report released on Friday...

Prothena (NASDAQ:PRTA) Price Target Raised to $12.00

Royal Bank Of Canada lifted their target price on shares of Prothena from $11.00 to $12.00 and gave the stock a "sector perform" rating in a report on Friday...

Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus

PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.

Prothena Q4 Earnings Call Highlights

Prothena (NASDAQ:PRTA) used its fourth-quarter and full-year 2025 results call to highlight partner-driven clinical momentum, updates from its wholly owned preclinical portfolio, and a sharper cash...

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

PRTA
Prothena Corporation plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PRTA News

PRTAProthena Corporation plc